Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Legislation (4)
- Consumer Protection Law (3)
- Health Law and Policy (3)
- Other Law (3)
- Antitrust and Trade Regulation (2)
-
- Computer Law (2)
- Entertainment, Arts, and Sports Law (2)
- Science and Technology Law (2)
- Administrative Law (1)
- Business Organizations Law (1)
- Commercial Law (1)
- Conflict of Laws (1)
- Contracts (1)
- Courts (1)
- Criminal Law (1)
- First Amendment (1)
- Food and Drug Law (1)
- Gaming Law (1)
- Internet Law (1)
- Law and Economics (1)
- Law and Society (1)
- Medical Jurisprudence (1)
- Public Law and Legal Theory (1)
- Transportation Law (1)
- Keyword
-
- Autonomous Vehicles; Toyota Motor Company; Volkswagon; General Motors; National Highway Traffic Safety Administration; Vehicle Regulation; Self-Driving Vehicles (1)
- Choice of law (1)
- Civil damages (1)
- Corporation (1)
- Drug Price Competition and Patent Term Restoration Act of 1984; Hatch-Waxman Act; Prescription Drug Prices; Generic Drug Manufacturers; Generic Drug Application Process; Consumer Protection; Reverse Payments; Citizen Petitions; Product Hopping; Misclassiication of Drugs; Mylan Pharmaceuticals; EpiPen; Price Gouging; Food and Drug Administration; Generic Drug User Fee Amendments of 2012 (GDUFA); Sherman Antitrust Act; Monopilization of the Pharmaceutical Industry; New Drug Application (NDA); Brand-Name Drug Application Process; Abbreviated New Drug Application (ANDA); Exclusive Right to Market; Federal Trade commission Act (FTCA); Unfair Methods of Competition; "Unfair or Deceptive Acts or Practices"; "Pay-for-Delay"; Patent Infringement; FTC v. Actavis; Administrative Procedure Act (APA); "Eleventh Hour" Petitions; Medicaid and Medicare; "Innovator" and "Non-Innovator" Drugs; Schemes to Coerce Patients; "Soft Switch"; Pharmacy Benefit Managers (PBMs); Oversight Committees; Proposed Amendments; Reverse Payment Penalty; (1)
-
- EEA (1)
- Economic Espionage Act (1)
- Economic loss (1)
- Economics (1)
- Federal civil statute (1)
- Federal courts (1)
- Federal statute (1)
- Hatch-Waxman; Hatch-Waxman Act; ANDA; FDA; 355(b)(1); 21 U.S.C.; Patent Information; False Patent Information; In re Actos; 848 F.3d 89; Disputed Patents; Mislabeled; Section viii; Sherman Act; Section 2; Monopoly; Antritrust; Orange Book; NDA; Patent Infringement (1)
- Intangible property (1)
- Interstate commerce (1)
- Misappropriation (1)
- NSPA (1)
- National Stolen Property Act (1)
- Publishing; Morals Clauses; Moral Turpitude; Contracts; Books; First Amendment; Authors; Cancel Culturel; Reverse Morals Clauses; Entertainment; Free Speech (1)
- Science; Technology; Patents; Health; Healthcare; Research and development; patent validity; trade secrecy; drugs; patent protection; biopharmaceutical companies; Intellectual Property; United States Patent and Trademark Office; Uniform Trade Secrets Act; Defend Trade Secrets Act; COVID-19; (1)
- Second Circuit (1)
- State law (1)
- Technology (1)
- Theft (1)
- Trade secrets (1)
- Transfer (1)
- United States v. Aleynikov (1)
- United States v. Angrawal (1)
- Youtube; Let's Play; Copyright; Unlicensed Copyright; Fair Use; Fair Use Doctrine; Nintendo; Let's Play videos; Copyright holders; Nintendo Creators Program; Fair use defense; contracts; contractual obligations; fan-created; recordings; video games; gamers; Twitch; user-generated; video hosting; revenue; DMCA; Content ID (1)
Articles 1 - 7 of 7
Full-Text Articles in Intellectual Property Law
Frustrating Morals: Is There An Implied Reverse Morals Clause In Publishing Agreements?, Matthew L. Fulton
Frustrating Morals: Is There An Implied Reverse Morals Clause In Publishing Agreements?, Matthew L. Fulton
Brooklyn Journal of Corporate, Financial & Commercial Law
In response to the #MeToo movement and the widespread condemnation of public figures for misconduct, book publishers adopted a standard contract provision used in other entertainment industries called a morals clause. Morals clauses allow a publisher to terminate the agreement if the author is subject to public condemnation. Although these provisions provide robust protection for publishers, these one-sided clauses provide no such protection for authors if publishers are subject to similar condemnation. Although authors may not have the leverage to negotiate reciprocal morals clauses, some authors may have an implied reverse morals clause through the frustration of purpose defense to …
Navigating A Multi-Billion Dollar Industry: Protecting Drug-Related Inventions To Further Research And Development, Minal Patel
Navigating A Multi-Billion Dollar Industry: Protecting Drug-Related Inventions To Further Research And Development, Minal Patel
Brooklyn Journal of Corporate, Financial & Commercial Law
Even with advancements in science and technology, pharmaceuticals continue to find themselves tethered to patent protection guidelines that once ensured revenue would continue to flow and provide funding for the next blockbuster drug or antibodies. However, as the Federal Circuit appears to inch towards unpredictability in the realm of patent validity, challenges involving patenting are imminent. In fact, gaps are forming in the ability of pharmaceuticals to further research and develop drugs. This Note proposes a solution that encapsulates a more precise standard supported by economic and policy rationales to determine patent validity. It begins with the general requirements of …
A Brand-Name Drug Company May Violate Section Two Of The Sherman Act By Mislabeling A Submitted Patent In The Orange Book: An Implication From In Re Actos End-Payor Antitrust Litigation, 848 F.3d 89 (2d Cir. 2017), Ping-Hsun Chen
Brooklyn Journal of Corporate, Financial & Commercial Law
The Hatch-Waxman Act encourages generic drug companies to submit an abbreviated new drug application (“ANDA”) for a generic version of a drug approved by the U.S. Food and Drug Administration (“FDA”). Nevertheless, a mechanism exists for a brand-name drug company to adjudicate a patent infringement dispute before the FDA approves an ANDA. The mechanism includes the regulatory scheme of patent information submission implemented by the FDA. 21 U.S.C. § 355(b)(1) requires that patent information be correct. False patent information destroys the objectives of the Hatch-Waxman Act. In re Actos End-Payor Antitrust Litigation, 848 F.3d 89 (2d Cir. 2017), may demonstrate …
Playing Fair: Youtube, Nintendo, And The Lost Balance Of Online Fair Use, Natalie Marfo
Playing Fair: Youtube, Nintendo, And The Lost Balance Of Online Fair Use, Natalie Marfo
Brooklyn Journal of Corporate, Financial & Commercial Law
Over the past decade, YouTube saw an upsurge in the popularity of “Let’s Play” videos. While positive for YouTube, this uptick was not without controversy. Let’s Play videos use unlicensed copyrighted materials, frustrating copyright holders. YouTube attempted to curb such usages by demonetizing and removing thousands of Let’s Play videos. Let’s Play creators struck back, arguing that the fair use doctrine protects their works. An increasing number of powerful companies, like Nintendo, began exploiting the ambiguity of the fair use doctrine against the genre; forcing potentially legal works to request permission and payment for Let’s Play videos, without a determination …
The Race Is On! Regulating Self-Driving Vehicles Before They Hit The Streets, Jack Liechtung
The Race Is On! Regulating Self-Driving Vehicles Before They Hit The Streets, Jack Liechtung
Brooklyn Journal of Corporate, Financial & Commercial Law
As the world braces itself for the unveiling of autonomous vehicles, the idea of regulation and oversight has gone largely undetected. Though some states have already begun enacting legislation ahead of the technology’s wide release, the regulatory landscape across the country is in disarray. It is imperative that both manufacturers and consumers be given some sort of uniform understanding as to how the automation is overseen throughout the manufacturing process and how liability will be levied in the case of inevitable mistakes on our nation’s roadways. This Note proposes that the National Highway Traffic Safety Administration be responsible for providing …
Abuse Of The Hatch-Waxman Act: Mylan's Ability To Monopolize Reflects Weaknesses, Kieran Meagher
Abuse Of The Hatch-Waxman Act: Mylan's Ability To Monopolize Reflects Weaknesses, Kieran Meagher
Brooklyn Journal of Corporate, Financial & Commercial Law
The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the Hatch-Waxman Act, is intended to lower the average price paid by consumers for prescription drugs. The Hatch-Waxman Act attempts to do so by simplifying the application process for generic drug manufacturers, allowing generic drug applications to circumvent the lengthy FDA testing and approval process that brand-name manufacturers must undergo. Though the Hatch-Waxman Act has successfully created a clear path to the market for generic drugs, it contains loopholes that allow brand name and generic companies to engage in practices aimed at maximizing monopoly profits, effectively …
Another Bite At The Apple For Trade Secret Protection: Why Stronger Federal Laws Are Needed To Protect A Corporation's Most Valuable Property, Alissa Cardillo
Another Bite At The Apple For Trade Secret Protection: Why Stronger Federal Laws Are Needed To Protect A Corporation's Most Valuable Property, Alissa Cardillo
Brooklyn Journal of Corporate, Financial & Commercial Law
Trade secrets are one of a corporation’s most valuable assets. However, they lack adequate protection under federal law, leaving them vulnerable to theft and misappropriation. As technology advances, it becomes easier and less time consuming for individuals and entities to access and steal trade secrets to a corporation’s detriment. Most often these thefts involve stealing trade secrets in an intangible form. Current legislation fails to adequately protect intangible trade secrets, leaving them vulnerable to theft. An amendment to the National Stolen Property Act that encompasses intangible trade secrets would close a loophole that currently exists relating to intangible assets, allowing …